Holen Sie sich die Stockscreener-App
0.8625
1.12%
-0.0087
Icecure Medical Ltd Aktie (ICCM) Neueste Nachrichten
Can a trend reversal in IceCure Medical Ltd lead to recoveryMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
ProSense® FDA authorization: IceCure gains U.S. marketing OK for low‑risk breast cancer in patients ≥70 - Stock Titan
What momentum indicators show for IceCure Medical Ltd stockPortfolio Risk Summary & Long-Term Growth Plans - newser.com
Investors push IceCure Medical (NASDAQ:ICCM) 13% lower this week, company's increasing losses might be to blame - simplywall.st
Pattern recognition hints at IceCure Medical Ltd upsideNew Guidance & Free Accurate Trade Setup Notifications - newser.com
New FDA-Approved Breast Cancer Treatment Freezes Tumors Instead Of Removing Them - essence.com
Brookline Capital Management Predicts IceCure Medical Q3 Earnings - MarketBeat
IceCure Medical to Attend the 2025 Maxim Growth Summit - Stock Titan
IceCure Medical (NASDAQ:ICCM) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
IceCure Medical : Company Presentation - MarketScreener
FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women - Medical Dialogues
IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50 - MarketBeat
HC Wainwright & Co. Maintains IceCure Medical (ICCM) Buy Recommendation - Nasdaq
IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright - Investing.com
IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright - TipRanks
ICCM: HC Wainwright & Co. Boosts Price Target to $2.50, Maintains Buy Rating | ICCM Stock News - GuruFocus
IceCure ProSense Cryoablation Receives FDA Marketing Authorization for Treating Low-Risk Breast Cancer in Women Aged 70+ - Imaging Technology News
Icecure gets FDA nod for Prosense cryoablation in breast cancer - BioWorld MedTech
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Yahoo Finance
Transcript : IceCure Medical LtdSpecial Call - MarketScreener
What MACD and RSI say about IceCure Medical Ltd2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for IceCure Medical LtdJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
IceCure Medical Ltd’s volatility index tracking explained2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
IceCure Medical Ltd stock prediction for this weekMarket Performance Recap & Reliable Breakout Forecasts - newser.com
What drives EcoSynthetix Inc 0Y8 stock priceStock Split Announcements & Rapid Wealth Building Tips - earlytimes.in
IceCure Medical Ltd Stock Analysis and ForecastPrice-to-Book Ratio Updates & Your Free Entry to Smart Investing Starts Here - earlytimes.in
IceCure Receives FDA Marketing Authorization for ProSense(R) Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
Using portfolio simulators with IceCure Medical Ltd includedJuly 2025 Retail & Safe Capital Investment Plans - newser.com
Key metrics from IceCure Medical Ltd’s quarterly dataQuarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Developing predictive dashboards with IceCure Medical Ltd data2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Is IceCure Medical Ltd stock attractive for growth ETFsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 49.8% in September - MarketBeat
IceCure Medical Surges on FDA Authorization for Breast Cancer Treatment - StocksToTrade
IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of "Buy" from Analysts - MarketBeat
IceCure Medical Ltd. Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
FDA approves IceCure cryoablation for breast cancer - MassDevice
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - Lelezard
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - Lelezard
ICCM Gains FDA Approval for ProSense Cryoablation System in Cert - GuruFocus
IceCure Receives FDA Marketing Authorization for ProSense® Cryoa - GuruFocus
Icecure Medical stock surges after FDA approves breast cancer treatment - Investing.com
IceCure Medical Gets FDA Approval for ProSense Breast Cancer Treatment; Shares Rise - MarketScreener
IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation - TipRanks
Full technical analysis of IceCure Medical Ltd stock2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
46,000 U.S. Women: IceCure Receives FDA Marketing Authorization for ProSense®; CPT III Covers $3,800 - Stock Titan
Detecting price anomalies in IceCure Medical Ltd with AILong Setup & Low Risk High Win Rate Picks - newser.com
Visualizing IceCure Medical Ltd stock with heatmapsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
0.57%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):